At close: December 13 at 4:00:02 PM EST
After hours: 7:58:52 PM EST
Research Analysis
Earnings Estimate
| Currency in USD | Current Qtr. (Dec 2024) | Next Qtr. (Mar 2025) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 3 | 2 | 3 | 3 |
| Avg. Estimate | -6.13 | -3.6 | -28.07 | -14.87 |
| Low Estimate | -7.4 | -5.6 | -29.2 | -23.6 |
| High Estimate | -4.4 | -1.6 | -26.4 | -5 |
| Year Ago EPS | -15.6 | -7.2 | -55.5 | -28.07 |
Revenue Estimate
| Currency in USD | Current Qtr. (Dec 2024) | Next Qtr. (Mar 2025) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 7 | 6 | 9 | 9 |
| Avg. Estimate | 25.8M | 37.72M | 72.13M | 247.27M |
| Low Estimate | 18M | 20M | 63M | 150.02M |
| High Estimate | 30.4M | 53.3M | 78.38M | 383.8M |
| Year Ago Sales | 7.83M | 18.57M | 29.5M | 72.13M |
| Sales Growth (year/est) | 229.38% | 103.10% | 144.55% | 242.79% |
Earnings History
| Currency in USD | 12/31/2023 | 3/31/2024 | 6/30/2024 | 9/30/2024 |
|---|---|---|---|---|
| EPS Est. | -11.2 | -8.2 | -6.8 | -7 |
| EPS Actual | -15.6 | -7.2 | -8.4 | -6.2 |
| Difference | -4.4 | 1 | -1.6 | 0.8 |
| Surprise % | -39.29% | 12.20% | -23.53% | 11.43% |
EPS Trend
| Currency in USD | Current Qtr. (Dec 2024) | Next Qtr. (Mar 2025) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | -6.13 | -3.6 | -28.07 | -14.87 |
| 7 Days Ago | -4.4 | -4.8 | -27 | -17.87 |
| 30 Days Ago | -4.4 | -4.8 | -27 | -17.87 |
| 60 Days Ago | -5.7 | -7.6 | -26.1 | -18.87 |
| 90 Days Ago | -6.67 | -7.6 | -29.8 | -21 |
EPS Revisions
| Currency in USD | Current Qtr. (Dec 2024) | Next Qtr. (Mar 2025) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | -- | 1 | -- | 1 |
| Up Last 30 Days | -- | 1 | -- | 1 |
| Down Last 7 Days | 1 | -- | 1 | 1 |
| Down Last 30 Days | 1 | -- | 1 | 1 |
Growth Estimates
| Current Qtr. | Next Qtr. | Current Year | Next Year | |
|---|---|---|---|---|
| BLUE | 60.68% | 50.00% | 49.43% | 47.03% |
| S&P 500 | 5.00% | 12.00% | 2.10% | 12.20% |
Upgrades & Downgrades
| Reiterates | RBC Capital: Sector Perform to Sector Perform | 11/15/2024 |
| Downgrade | B of A Securities: Buy to Neutral | 11/15/2024 |
| Maintains | Barclays: Overweight to Overweight | 11/15/2024 |
| Maintains | Wells Fargo: Equal-Weight to Equal-Weight | 9/25/2024 |
| Reiterates | Cantor Fitzgerald: Neutral | 9/16/2024 |
| Maintains | B of A Securities: Buy to Buy | 8/15/2024 |
Related Tickers
EDIT Editas Medicine, Inc.
1.4400
-23.81%
TSVT 2seventy bio, Inc.
3.2700
-2.10%
IBRX ImmunityBio, Inc.
2.8700
-5.59%
QURE uniQure N.V.
15.40
+2.26%
LXRX Lexicon Pharmaceuticals, Inc.
0.8103
-1.45%
CRSP CRISPR Therapeutics AG
43.78
-3.57%
CMRX Chimerix, Inc.
2.9500
+0.34%
NTLA Intellia Therapeutics, Inc.
12.90
-4.87%
BEAM Beam Therapeutics Inc.
27.93
-0.46%
MGX Metagenomi, Inc.
3.2400
-16.06%